The Centers for Medicare & Medicaid Services (CMS) requests Medicare Administrative Contractors (MACs) utilize three new HCPCS codes in the HCPCS file: Q5103 Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg; Q5104 Injection, infliximab-abda, biosimilar, (renflexis), 10 mg; and Q2041 Axicabtagene Ciloleucel, up to 200 million autologous Anti-CD19 CAR T Cells, Including leukapheresis and dose preparation procedures, per infusion, according to provided CMS instructions.
Subject: Quarterly Healthcare Common Procedure Coding System (HCPCS) Drug/Biological Code Changes -April 2018 Update
Release Date: March 7, 2018
Effective Date: April 1, 2018
Implementation Date: April 2, 2018
Special Notes: Transmittal 3966, dated February 2, 2018, is being rescinded and replaced by Transmittal 3997, dated, March 7, 2018, Year to add business requirement 10454.7. All other information remains the same.